Skip to main content
OpenTrials
Completed

NCT Number: NCT02481193

Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia

The purpose of this study is to investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Purpose: To investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.

Methods: Ninety patients scheduled for laparoscopic cholecystectomies were equally randomized into three groups to receive pretreatment of 0.005, 0.01, and 0.02 mg/kg cisatracurium, respectively. General anesthesia was induced 3.5 min later, train of four stimulation was monitored 4.5 min later, succinylcholine 1.5 mg/kg was injected 5 min later, and endotracheal intubation was implemented 6.5 min later. The side effects of cisatracurium, intensity of fasciculations, intubating conditions, time and extent to maximal depression of twitch and time for its recovery to 20% of control value, severity of myalgia at 24 h postoperatively, serum potassium before the induction, at the time of endotracheal intubation, and 5 min after intubation were recorded.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • American Standards Association (ASA) physical status I or II patients scheduled for elective laparoscopic cholecystectomies with tracheal intubation requiring general anesthesia
  • 20 - 65 years old
  • without acid-base imbalance and electrolyte disturbance
  • with normal hepatic and renal function

Exclusion criteria

  • Patients with known hyperkalemia
  • Patients with increased intraocular pressure
  • Patients with increased intracranial pressure
  • Patients with symptoms of gastroesophageal reflux
  • Patients with anticipated airway difficulties
  • Patients with malignant fever
  • Patients with neuromuscular disease
  • Patients with burn or crush injuries
  • Patients with taking drugs known to alter the action of neuromuscular blockers
  • Patients with with a body mass index exceeding 30

Treatment and study plan

Cisatracurium

Drug

Different doses of cisatracurium pretreatment

Other names: Dose

Primary outcomes

  1. The presence of fasciculations

    Time frame: After the injection of succinylcholine for 1.5 minutes

Secondary outcomes

  1. Side effects of the pretreatment of cisatracurium

    Time frame: At the time of three minutes after the pretreatment of cisatracurium

  2. The time to maximal depression of twitch

    Time frame: From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes

  3. The extent to maximal depression of twitch

    Time frame: From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes

  4. The time for twitch recovery to 20% of its control value

    Time frame: From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes

  5. The grades of endotracheal intubation

    Time frame: At intubating time

  6. The changes of serum potassium

    Time frame: After entering the operating theater till the anesthesia induction, at intubating, and 5 min after intubation

  7. Myalgia at 24 hours postoperatively

    Time frame: At 24 hours postoperatively

Sponsors and collaborators

Lead sponsor

Yangzhou No.1 People's Hospital

Other

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Jun 25, 2015
Registry last updated
Jun 25, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.